FDA bioterrorism programs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CDER bioterrorism efforts will be coordinated by the Office of Review Management's new Office of Pediatric Drug Development and Special Initiatives, under the direction of FDA's Dianne Murphy, MD. CDER efforts will focus on development of drugs to treat smallpox and plague, while CBER will focus on fostering development of new vaccines for smallpox and anthrax. In the wake of the Sept. 11 terrorist attacks, FDA bioterrorism programs will receive a higher priority with hopes for a staffing increase in 2002 as more government resources become available. The Office of Science Coordination and Communication's Andrea Meyerhoff directs the overall FDA bioterrorism effort